Abstract
Plan: The objective of this study was to develop Gastric floating drug delivery system containing Metoprolol and having a bulk density lower than that of gastric fluid remaining buoyant on the stomach contents. Preface: Metaprolol tartarate is having short to moderate half life 3-7 hrs, low bioavailability hence it is worth able to formulate Metaprolol in floating drug delivery. The GRDDS can improve the controlled delivery of the drugs which exhibit an absorption window by continuously releasing the drug for a prolonged period before it reaches its absorption site, thus ensuring its optimal bioavailability Methodology: Percentage drug content in all floating tablet formulations was found to be 95.85% to 103.33% which was within Pharmacopoeial limit. In- vitro drug release profile from all formulations (F1-F10) showed sustained release of Metoprolol Tartarate over a period of 10 hours. Outcome: Among all the formulation, F3 showed drug release up to 94.71% at the end of 10 hours. The mechanism of the drug release from F3 was anomalous transport, first order release kinetics. Stability studies on optimized batch showed no significant effect on physical properties, drug content, floating behavior and drug release.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
